“Success is the sum of small efforts, repeated day in and day out.”
– Robert Collier
| December 2025: Visiting student from the University of Melbourne joins our lab |
|---|
| In the final month of 2025, our lab was pleased to welcome a visiting student, Anh Thuy-Tram Nguyen, from the University of Melbourne, Australia. During her stay, she will conduct a virtual screening campaign on DAPK1 (death associated protein kinase 1) to identify novel anticancer agents. |
| October 2025: Warm welcome to Phong Lam on his visit back to the lab |
|---|
| We’re delighted to welcome back Phong Lam, our former lab member, who has just completed his Master’s degree at Uppsala University and shared an inspiring talk with us today! A memorable photo from the visit can be found here. |
| October 2025: New study on α-glucosidase inhibition by olaximpentaose |
|---|
| Through a great collaboration with colleagues at HCMC UTE, I had the opportunity to explore the binding mechanism of a newly discovered triterpenoid, olaximpentaose, from Olax imbricata, which showed stronger α-glucosidase inhibition than acarbose. Our paper has just been published in Natural Product Research and can be accessed here. |
| July 2025: Our first visiting student |
|---|
| We are deglighted to welcome Thy Nguyen-Anh Vo, a high school student from Saint John Northwestern Academy, Wisconsin, USA, to our lab as a visiting student. She will be working on an exciting project on MASLD (Metabolic dysfunction–associated steatotic liver disease), and we hope she will have a rewarding experience in our lab. |
| Apr 2025: 41st Pharmaceutical Science and Technology Conference at UMP |
|---|
| We are excited to participate in the 41st Pharmaceutical Science and Technology Conference on April 10–11, 2025, at the Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, with 7 poster presentations. |
| Feb 2025: Targeting ABL1 Kinase – New Study Published in RSC Advances |
|---|
| Our paper, “2-Amino-4,6-diarylpyrimidines as Potential Chronic Myeloid Leukemia Cell Inhibitors Targeting Anti-ABL1 Kinase: Microwave-Assisted Synthesis, Biological Evaluation, Molecular Docking, and Dynamics Studies,” has been accepted in RSC Advances. This study integrates computational and experimental approaches to explore novel ABL1 kinase inhibitors, with molecular docking and dynamics simulations providing insights into binding modes and affinity predictions. |
| Jan 2025: Small-Molecule Inhibitors for Dengue: Advances and Strategies |
|---|
| Our paper, “Achievements and Approaches in the Search for Small-Molecule Dengue NS2B/NS3 Inhibitors,” has been accepted in Current Medicinal Chemistry. The study reviews recent efforts to develop NS2B/NS3 protease inhibitors, examining promising compounds, structural insights, and challenges in antiviral drug discovery. |
| Jan 2025: Computational Insights into SARS-CoV-2 Variant Binding Published in Journal of Biomolecular Structure and Dynamics |
|---|
| Our recent work, “Binding Ability of Delta and Omicron Towards the Angiotensin-Converting Enzyme 2 Receptor and Antibodies: A Computational Study,” has been accepted in Journal of Biomolecular Structure and Dynamics. Using computational modeling, we analyze how mutations in Delta and Omicron influence their binding to ACE2 and neutralizing antibodies, offering new perspectives on viral evolution and immune evasion. |
| Jan 2025: Paper Accepted in Medicinal Chemistry |
|---|
| Our paper, “Synthesis and Evaluation of Antibacterial and Antifungal Activities In vitro and In silico of Novel Morpholinoalkoxychalcones,” has been accepted in Medicinal Chemistry. The study leverages molecular docking to elucidate the antibacterial mechanisms of newly synthesized morpholinoalkoxychalcones, contributing to the development of novel antimicrobial agents. |
“Success always demands a greater effort.”
– Winston S. Churchill
Tan Thanh Mai 